Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

mFOLFIRINOX

A

Agent Score

ESMO-MCBS v1.1

Scorecard version: 1

Indication details

Tumour Type: Gastrointestinal Cancers
Tumour Sub-type: Pancreatic cancer
Tumour stage: Early
Control Arm: Gemcitabine
Treatment Setting: Resected pancreatic ductal adenocarcinoma
Trial Name: PRODIGE 24/CCTG PA. 6 trial

Primary Outcome(s)

Primary Outcome(s): OS
Form(s): Form 1

Outcome Data

OS Control: 35.0 months
OS Gain: 19.4 months 3-year survival gain 14.8%
OS HR: 0.64 (0.48-0.86)
Toxicity Comment: Increased acute toxicity

Final Score (after adjustments)

Final curative score: A
Release date: 14.05.2019